替雷利珠单抗联合顺铂化疗方案治疗中晚期非小细胞肺癌的临床疗效

Clinical Efficacy of Tirellizumab Combined with Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer

目的探究替雷利珠单抗与顺铂化疗治疗中晚期非小细胞肺癌的作用。方法方便选取2021年7月—2023年6月南京大学医学院附属盐城第一医院呼吸与危重症医学科收治的384例中晚期非小细胞肺癌患者为研究对象,采用密闭信封法分为对照组(n=192)、研究组(n=192)。对照组采取顺铂化疗方案,研究组在此基础上联合静脉滴注替雷利珠单抗治疗。治疗前及治疗4个周期后,检测并计算两组患者中性粒细胞/淋巴细胞比值(Neutrophil/Lymphocyte Ratio,NLR)、血小板/淋巴细胞比值(Platelet/Lymphocyte Ratio,PLR)、系统性免疫性炎症指数(Systemic Immune-inflammation Index,SII)水平;对比两组患者临床疗效及不良反应发生率。结果研究组疾病缓解率高于对照组,差异有统计学意义(P<0.05);治疗前,两组患者炎症水平比较,差异无统计学意义(P>0.05);治疗后,研究组NLR为2.05±1.19、PLR为123.58±29.32、SII为158.56±31.73,均低于对照组,差异有统计学意义(t=5.674、6.828、18.476,P均<0.001);研究组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论中晚期非小细胞肺癌应用替雷利珠单抗联合顺铂化疗方案,可提高疗效,减轻机体炎症反应,并减少不良反应,安全性高。

Objective To explore the effect of tirellizumab and cisplatin chemotherapy in advanced non-small cell lung cancer.Methods A total of 384 patients with advanced non-small cell lung cancer admitted to the Department of Respiratory and Critical Care Medicine,Yancheng First Hospital Affiliated to Nanjing University School of Medicine from July 2021 to June 2023 were conveniently selected as the study objects,and were divided into control group(n=192)and study group(n=192)by sealed envelope method.The control group received cisplatin chemotherapy,and the study group received intravenous tirellizumab on this basis.Before and after 4 cycles of treatment,to check and calculate the two groups of neutrophils/lymphocyte ratio(NLR),platelet/lymphocyte ratio(PLR),systemic immuneinflammation index(SII)levels;the clinical efficacy and incidence of adverse reactions were compared between patients in two groups.Results The remission rate of disease in the study group was higher than that in the control group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in levels of inflammatory response between patients in two groups(P>0.05).After treatment,NLR was(2.05±1.19),PLR was(123.58±29.32)and SII was(158.56±31.73)in the study group were lower than those in the control group,the differences were statistically significant(t=5.674,6.828,18.476,all P<0.001).The incidence of adverse reactions in study group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion Tirellizumab combined with cisplatin can improve the therapeutic effect,reduce inflammation,and reduce adverse reactions in patients with advanced non-small cell lung cancer with high safety.